Home >> Signaling Pathways >> Angiogenesis

Angiogenesis

Products for  Angiogenesis

  1. Cat.No. Product Name Information
  2. GC38767 Deoxyshikonin A natural products with anti-tumor activity Deoxyshikonin  Chemical Structure
  3. GC32449 Desidustat An inhibitor of HIF-PH Desidustat  Chemical Structure
  4. GC47234 Diosmetin-d3 An internal standard for the quantification of diosmetin Diosmetin-d3  Chemical Structure
  5. GC45767 Dovitinib-d8 An internal standard for the quantification of dovitinib Dovitinib-d8  Chemical Structure
  6. GC19128 E7820 E7820 is an angiogenesis inhibitor by suppressing integrin a2, a cell adhesion molecule expressed on endothelial cells. E7820  Chemical Structure
  7. GC18236 Echinomycin An inhibitor of HIF1mediated gene transcription Echinomycin  Chemical Structure
  8. GC62182 Echistatin TFA Echistatin TFA, the smallest active RGD protein belonging to the family of disintegrins that are derived from snake venoms, is a potent inhibitor of platelet aggregation. Echistatin TFA  Chemical Structure
  9. GC17236 Echistatin, α1 isoform Echistatin, α1 isoform, the smallest active RGD protein belonging to the family of disintegrins that are derived from snake venoms, is a potent inhibitor of platelet aggregation. Echistatin, α1 isoform  Chemical Structure
  10. GC33043 EL-102 EL-102 is a hypoxia-induced factor 1 (Hif1α) inhibitor. EL-102 induces apoptosis, inhibits tubulin polymerisation and shows activities against prostate cancer. EL-102 can be used for the research of cancer. EL-102  Chemical Structure
  11. GC64819 Elsubrutinib Elsubrutinib (ABBV-105) is an orally active, potent, selective and irreversible Bruton's tyrosine kinase (BTK) inhibitor。The IC50 of Elsubrutinib for BTK catalytic domain is 0.18 μM. Elsubrutinib  Chemical Structure
  12. GC33634 Enarodustat (JTZ-951) Enarodustat (JTZ-951) is a potent and orally active hypoxia-inducible factor prolyl hydroxylase inhibitor, with an EC50 of 0.22 μM. Enarodustat (JTZ-951)  Chemical Structure
  13. GC60807 ENMD-1068 hydrochloride Selective protease-activated receptor 2 (PAR2) anatagonist ENMD-1068 hydrochloride  Chemical Structure
  14. GC33170 ENMD-119 (ENMD 1198) ENMD-119 (ENMD 1198) (IRC-110160), an orally active microtubule destabilizing agent, is a 2-methoxyestradiol analogue with antiproliferative and antiangiogenic activity. ENMD-119 (ENMD 1198) is suitable for inhibiting HIF-1alpha and STAT3 in human HCC cells and leads to reduced tumor growth and vascularization. ENMD-119 (ENMD 1198)  Chemical Structure
  15. GC12447 Eptifibatide Acetate

    Glycoprotein (GP) IIb/IIIa inhibitor

    Eptifibatide Acetate  Chemical Structure
  16. GC68283 Etrolizumab Etrolizumab  Chemical Structure
  17. GC47328 Everolimus-d4 An internal standard for the quantification of everolimus Everolimus-d4  Chemical Structure
  18. GC34062 Evobrutinib (M2951)

    Evobrutinib, as an orally, highly selective, covalent Bruton's tyrosine kinase inhibitor, was well‐tolerated and effective.

    Evobrutinib (M2951)  Chemical Structure
  19. GC16638 FG2216 HIF-prolyl hydroxylase inhibitor FG2216  Chemical Structure
  20. GC14804 Firategrast Firategrast  Chemical Structure
  21. GC32562 Fradafiban (BIBU-52) Fradafiban (BIBU-52) is a nonpeptide platelet glycoprotein IIb/IIIa antagonist, which binds to the human platelet GP IIb/IIIa complex with a Kd value of 148 nM. Fradafiban (BIBU-52)  Chemical Structure
  22. GC38044 Fraxinellone Fraxinellone  Chemical Structure
  23. GC61501 FSLLRY-NH2 TFA FSLLRY-NH2 TFA is a protease-activated receptor 2 (PAR2) inhibitor. FSLLRY-NH2 TFA  Chemical Structure
  24. GC43727 Ganglioside GD1a mixture (sodium salt)

    Ganglioside GD1a is a sialic acid-containing glycosphingolipid found in brain, erythrocytes, bone marrow, testis, spleen, and liver.

    Ganglioside GD1a mixture (sodium salt)  Chemical Structure
  25. GC43732 Ganglioside GM3 Mixture (sodium salt) Ganglioside GM3 is a monosialoganglioside that demonstrates antiproliferative and proapoptotic effects in tumor cells by modulating cell adhesion, proliferation, and differentiation. Ganglioside GM3 Mixture (sodium salt)  Chemical Structure
  26. GC36125 GB-110 GB-110 is a potent, orally active, and nonpeptidic protease activated receptor 2 (PAR2) agonist. GB-110  Chemical Structure
  27. GC38329 GB-110 hydrochloride GB-110 hydrochloride is a potent, orally active, and nonpeptidic protease activated receptor 2 (PAR2) agonist. GB-110 hydrochloride  Chemical Structure
  28. GC65439 GB-88 GB-88 is an oral, selective non-peptide antagonist of PAR2, inhibits PAR2 activated Ca2+ release with an IC50 of 2 ?M. GB-88  Chemical Structure
  29. GC11995 GDC-0834 GDC-0834 is the S-enantiomer of GDC-0834. GDC-0834  Chemical Structure
  30. GC36127 GDC-0834 Racemate Racemic form of GDC-0834 GDC-0834 Racemate  Chemical Structure
  31. GC19162 GDC-0853 GDC-0853 (GDC-0853) is a potent, selective, orally available, and noncovalent bruton's tyrosine kinase (Btk) inhibitor with Kis of 0.91 nM, 1.6, 1.3, 12.6, and 3.4 nM for WT Btk, and the C481S, C481R, T474I, T474M mutants. GDC-0853 has the potential for rheumatoid arthritis and systemic lupus erythematosus research. GDC-0853  Chemical Structure
  32. GC47398 Genistein-d4 An internal standard for the quantification of genistein Genistein-d4  Chemical Structure
  33. GC19167 GLPG0187 An αν?integrin receptor antagonist GLPG0187  Chemical Structure
  34. GC30263 Glucosamine (D-Glucosamine) Glucosamine (D-Glucosamine) (D-Glucosamine (D-Glucosamine)) is an amino sugar and a prominent precursor in the biochemical synthesis of glycosylated proteins and lipids, is used as a dietary supplement. Glucosamine (D-Glucosamine)  Chemical Structure
  35. GC30223 Gly-Arg-Gly-Asp-Ser Gly-Arg-Gly-Asp-Ser is a pentapeptide that forms the cell-binding domain of a glycoprotein, osteopontin. Gly-Arg-Gly-Asp-Ser  Chemical Structure
  36. GC34595 GN44028 A HIF-1 inhibitor GN44028  Chemical Structure
  37. GC13951 GR 144053 trihydrochloride platelet fibrinogen receptor glycoprotein IIb/IIIa (GpIIb/IIIa) antagonist GR 144053 trihydrochloride  Chemical Structure
  38. GC33323 GRGDSP GRGDSP, a synthetic linear RGD peptide, is an integrin inhibitor. GRGDSP  Chemical Structure
  39. GC34265 GRGDSP TFA GRGDSP (TFA) is an integrin inhibitor. GRGDSP TFA  Chemical Structure
  40. GC43803 HA-1077 (hydrochloride) Fasudil (HA-1077; AT877) dihydrochloride is a nonspecific RhoA/ROCK inhibitor and also has inhibitory effect on protein kinases, with an Ki of 0.33 μM for ROCK1, IC50s of 0.158 μM and 4.58 μM, 12.30 μM, 1.650 μM for ROCK2 and PKA, PKC, PKG, respectively. HA-1077 (hydrochloride) is also a potent Ca2+ channel antagonist and vasodilator. HA-1077 (hydrochloride)  Chemical Structure
  41. GC49882 Hemokinin 1 (human) (trifluoroacetate salt) A peptide agonist of NK1 receptors Hemokinin 1 (human) (trifluoroacetate salt)  Chemical Structure
  42. GC39146 HIF-1 inhibitor-1 An inhibitor of HIF-1 signaling HIF-1 inhibitor-1  Chemical Structure
  43. GC31358 HIF-2α-IN-1 HIF-2α-IN-1 is a HIF-2α inhibitor has an IC50 of less than 500 nM in HIF-2α scintillation proximity assay. HIF-2α-IN-1  Chemical Structure
  44. GC11767 Hydralazine HCl Hydralazine HCl is a orally active antihypertensive agent, reduces peripheral resistance directly by relaxing the smooth muscle cell layer in arterial vessel. Hydralazine HCl  Chemical Structure
  45. GC64979 I-191 I-191 is a potent, selective protease-activated receptor 2 (PAR2) antagonist. I-191  Chemical Structure
  46. GC39194 Ibrutinib D5 Ibrutinib D5 (PCI-32765 D5) is a deuterium labeled Ibrutinib. Ibrutinib is a selective, irreversible Btk inhibitor. Ibrutinib D5  Chemical Structure
  47. GC60197 Ibrutinib deacryloylpiperidine Ibrutinib deacryloylpiperidine (IBT4A) is an impurity of Ibrutinib. Ibrutinib is a selective, irreversible Btk inhibitor with an IC50 of 0.5 nM. Ibrutinib deacryloylpiperidine  Chemical Structure
  48. GC36289 Ibrutinib-biotin Ibrutinib-biotin is a probe that consists of Ibrutinib linked to biotin via a long chain linker, extracted from patent WO2014059368A1 Compound 1-5, has an IC50 of 0.755-1.02 nM for BTK. Ibrutinib-biotin  Chemical Structure
  49. GC32948 IDF-11774 A novel HIF-1 inhibitor IDF-11774  Chemical Structure
  50. GC34301 ILK-IN-2 ILK-IN-2 (OSU-T315 analog) is a ILK inhibitor. ILK-IN-2  Chemical Structure
  51. GC60200 ILK-IN-3 ILK-IN-3 is an integrin linked kinase inhibitor with antitumor activity. ILK-IN-3  Chemical Structure
  52. GC47454 IMS 2186 An anti-choroidal neovascularization agent IMS 2186  Chemical Structure
  53. GC32967 Integrin Antagonists 27 Integrin Antagonists 27 is a small molecule integrin αvβ3 antagonist with binding affinity of 18 nM, as s novel anticancer agent. Integrin Antagonists 27  Chemical Structure
  54. GC61613 Integrin modulator 1 Integrin modulator 1 is a potent and selective α4β1 integrin agonist, with an IC50 of 9.8 nM for RGD-binding α4β1. Integrin modulator 1  Chemical Structure
  55. GC12255 IOX4 PHD2 inhibitor IOX4  Chemical Structure
  56. GC32787 iRGD peptide (c(CRGDKGPDC)) iRGD peptide (c(CRGDKGPDC)) is a 9-amino acid cyclic peptide, triggers tissue penetration of drugs by first binding to av integrins, then proteolytically cleaved in the tumor to produce CRGDK/R to interact with neuropilin-1, and has tumor-targeting and tumor-penetrating properties. iRGD peptide (c(CRGDKGPDC))  Chemical Structure
  57. GC38801 Irigenin Irigenin is a is a lead compound, and mediates its anti-metastatic effect by specifically and selectively blocking α9β1 and α4β1 integrins binding sites on C-C loop of Extra Domain A (EDA). Irigenin shows anti-cancer properties. It sensitizes TRAIL-induced apoptosis via enhancing pro-apoptotic molecules in gastric cancer cells. Irigenin  Chemical Structure
  58. GC15379 JNJ-42041935 Hypoxia-inducible factor (HIF) prolyl hydroxylase (PHD) inhibitor JNJ-42041935  Chemical Structure
  59. GC50642 LDV α4β1 (VLA-4) ligand LDV  Chemical Structure
  60. GC16190 LDV FITC fluorescent ligand that binds to the α4β1 integrin (VLA-4) LDV FITC  Chemical Structure
  61. GC17263 Leukadherin 1 CD11b/CD18 activator Leukadherin 1  Chemical Structure
  62. GC14857 LFM-A13 BTK-specific tyrosine kinase inhibitor LFM-A13  Chemical Structure
  63. GC19222 Lifitegrast Lifitegrast is an integrin lymphocyte function-associated antigen-1 (LFA-1) antagonist; inhibits Jurkat T cell attachment to ICAM-1 with an IC50 of 2.98 nM. Lifitegrast  Chemical Structure
  64. GC13227 LRGILS-NH2 Protease-activated receptor agonist LRGILS-NH2  Chemical Structure
  65. GC47582 Lupulone A beta-acid Lupulone  Chemical Structure
  66. GC32724 LW6 (HIF-1α inhibitor) LW6 (HIF-1α inhibitor) (HIF-1α inhibitor) is a novel HIF-1 inhibitor with an IC50 of 4.4 μM. LW6 (HIF-1α inhibitor) decreases HIF-1α protein expression without affecting HIF-1β expression. LW6 (HIF-1α inhibitor)  Chemical Structure
  67. GC36500 LXW7 LXW7, a cyclic peptide containing Arg-Gly-Asp (RGD), is an integrin αvβ3 inhibitor. LXW7  Chemical Structure
  68. GC40865 LYG-202 LYG-202 is a synthetic flavonoid with anticancer and anti-angiogenic activities. LYG-202  Chemical Structure
  69. GC32055 MK-0429 (L-000845704) MK-0429 (L-000845704) (L-000845704) is an orally active, potent, selective and nonpeptide pan-integrin antagonist with IC50 values of 1.6 nM, 2.8 nM, 0.1 nM, 0.7 nM, 0.5 nM and 12.2 nM for αvβ1, αvβ3, αvβ5, αvβ6, αvβ8 and α5β1, respectively. MK-0429 (L-000845704)  Chemical Structure
  70. GC19251 MK-8617 MK-8617 is an orally active pan-inhibitor of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) with an IC50 of 1 nM for PHD2. MK-8617  Chemical Structure
  71. GC13004 ML161 Reversible inhibitor of PAR1-mediated platelet activation ML161  Chemical Structure
  72. GC18608 MMP-2/MMP-9 Inhibitor II MMP-2/MMP-9 inhibitor II is a dual inhibitor of matrix metalloproteinase-2 (MMP-2) and MMP-9 (IC50s = 17 and 30 nM, respectively). MMP-2/MMP-9 Inhibitor II  Chemical Structure
  73. GC18616 MMP-8 Inhibitor I MMP-8 Inhibitor I is a selective inhibitor of the neutrophil collagenase matrix metalloproteinase-8 (MMP-8) with an IC50 value of 4 nM. MMP-8 Inhibitor I  Chemical Structure
  74. GC10048 MNS Inhibitor of Src/Syk tyrosine kinases MNS  Chemical Structure
  75. GC10046 Molidustat (BAY85-3934) Molidustat (BAY85-3934) (BAY 85-3934) is a novel inhibitor of hypoxia-inducible factor prolyl hydroxylase (HIF-PH) with mean IC50 values of 480 nM for PHD1, 280 nM for PHD2, and 450 nM for PHD3. Molidustat (BAY85-3934)  Chemical Structure
  76. GC36661 MT-802 MT-802 is a potent BTK degrader based on Cereblon ligand, with a DC50 of 1 nM. MT-802  Chemical Structure
  77. GC49686 N-desmethyl Regorafenib N-oxide An active metabolite of regorafenib N-desmethyl Regorafenib N-oxide  Chemical Structure
  78. GC62255 N-piperidine Ibrutinib hydrochloride N-piperidine Ibrutinib hydrochloride (Compound 1) is a reversible Ibrutinib derivative. N-piperidine Ibrutinib hydrochloride is a potent BTK inhibitor with IC50s of 51.0 and 30.7 nM for WT BTK and C481S BTK, respectively. N-piperidine Ibrutinib hydrochloride can be used as a BTK ligand in the synthesis of a series of PROTACs, such as SJF620. SJF620 is a potent PROTAC BTK degrader with a DC50 of 7.9 nM. N-piperidine Ibrutinib hydrochloride  Chemical Structure
  79. GC44290 NAADP (sodium salt)

    Nicotinic acid adenine dinucleotide phosphate (NAADP) is a secondary messenger that induces calcium mobilization.

    NAADP (sodium salt)  Chemical Structure
  80. GC61109 Natalizumab Natalizumab is a recombinant, humanized IgG4 monoclonal antibody, binds to α4β1-integrin and blocks its interaction with vascular cell adhesion molecule-1 (VCAM-1). Natalizumab  Chemical Structure
  81. GC44465 NSC 12 NSC 12 is an extracellular trap for fibroblast growth factor 2 (FGF2) that binds FGF2 (Kd = 51 μM) and interferes with its interaction with FGFR1, without affecting the ability of FGF2 to bind heparin or heparin sulfate proteoglycans (HSPGs). NSC 12  Chemical Structure
  82. GC69600 NX-2127

    NX-2127 is an orally effective BTK inhibitor that can induce the degradation of mutated BTKC481S in cells. NX-2127 inhibits the proliferation of TMD8 cells with the BTKC481S mutation more effectively than Ibrutinib. NX-2127 catalyzes the degradation of Ikaros (IKZF1) and Aiolos (IKZF3), corresponding to concentrations of 25 nM and 54 nM, respectively. NX-2127 stimulates T cell activation and increases IL-2 production in primary human T cells.

    NX-2127  Chemical Structure
  83. GC49349 O-Desethyl Sildenafil A metabolite of sildenafil O-Desethyl Sildenafil  Chemical Structure
  84. GC16107 Obtustatin An integrin α1β1 inhibitor Obtustatin  Chemical Structure
  85. GC17358 Octyl-α-ketoglutarate prolyl hydroxylases (PHD) activator Octyl-α-ketoglutarate  Chemical Structure
  86. GC15199 OGT 2115 Heparanase inhibitor OGT 2115  Chemical Structure
  87. GC12821 Oltipraz Nrf2 activator;An antischistosomal agent Oltipraz  Chemical Structure
  88. GC13219 ONO-4059 ONO-4059 is the analog of ONO-4059, ONO-4059 is a highly potent and selective Btk inhibitor. ONO-4059  Chemical Structure
  89. GC69630 Orbofiban acetate

    Orbofiban acetate is an orally active platelet membrane glycoprotein IIb/IIIa antagonist that inhibits platelet aggregation.

    Orbofiban acetate  Chemical Structure
  90. GC41625 Oroxylin A

    Oroxylin A is a flavonoid that has been found in S.

    Oroxylin A  Chemical Structure
  91. GC36821 OSU-T315 OSU-T315 (ILK-IN-1) is a small Integrin-linked kinase (ILK) inhibitor with an IC50 of 0.6 μM, inhibiting PI3K/AKT signaling by dephosphorylation of AKT-Ser473 and other ILK targets (GSK-3β and myosin light chain). OSU-T315 abrogates AKT activation by impeding AKT localization in lipid rafts and triggers caspase-dependent apoptosis in an ILK-independent manner. OSU-T315 causes cell death through apoptosis and autophagy. OSU-T315  Chemical Structure
  92. GC11753 P11 P11 is an antagonist of the integrin αvβ3-vitronectin interaction, with an IC50 of 1.74 pg/mL (2.414 pM). P11  Chemical Structure
  93. GC11951 PAR 4 (1-6)

    PAR4 agonist

    PAR 4 (1-6)  Chemical Structure
  94. GC62101 PAR-2-IN-1 PAR-2-IN-1 is a protease-activated receptor-2 (PAR2) signaling pathway inhibitor with anti-inflammatory and anticancer effects. PAR-2-IN-1  Chemical Structure
  95. GA23350 PAR-3 (1-6) amide (human) PAR-3 (1-6) amide (human) is a proteinase-activated receptor (PAR-3) agonist peptide. PAR-3 (1-6) amide (human)  Chemical Structure
  96. GC33599 PAR-4 Agonist Peptide, amide TFA (PAR-4-AP (TFA)) PAR-4 Agonist Peptide, amide TFA (PAR-4-AP (TFA)) (PAR-4-AP TFA; AY-NH2 TFA) is a proteinase-activated receptor-4 (PAR-4) agonist, which has no effect on either PAR-1 or PAR-2 and whose effects are blocked by a PAR-4 antagonist. PAR-4 Agonist Peptide, amide TFA (PAR-4-AP (TFA))  Chemical Structure
  97. GC15817 PAR-4 Agonist Peptide, amide (AY-NH2) PAR-4 Agonist Peptide, amide(AY-NH2) (PAR-4-AP; AY-NH2) is a proteinase-activated receptor-4 (PAR-4) agonist, which has no effect on either PAR-1 or PAR-2 and whose effects are blocked by a PAR-4 antagonist. PAR-4 Agonist Peptide, amide (AY-NH2)  Chemical Structure
  98. GC38134 Parmodulin 2 Reversible inhibitor of PAR1mediated platelet activation Parmodulin 2  Chemical Structure
  99. GC69663 Parstatin(mouse) TFA

    Parstatin (mouse) TFA is a peptide agonist of the PAR-1 thrombin receptor with cell-penetrating properties and an effective inhibitor of angiogenesis.

    Parstatin(mouse) TFA  Chemical Structure
  100. GC40085 Pazopanib-d6 Pazopanib-d6 is intended for use as an internal standard for the quantification of pazopanib by GC- or LC-MS. Pazopanib-d6  Chemical Structure
  101. GC36861 PCI 29732 A multi-kinase inhibitor PCI 29732  Chemical Structure

Items 101 to 200 of 295 total

per page
  1. 1
  2. 2
  3. 3

Set Descending Direction